News

ascopubs.org5d
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after ...
Stratum A (post-neoadjuvant) 83.1 (77.1-87.8) 76.6 (69.6-82.1) 0.67 (0.44-1.03) 0.06 Clinical trial identification: EUDRACT 2016-000189-45. Legal entity responsible for the study: Department of ...